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Abstract
Aims-To study the expression of inter-
leukin-2 receptor (IL-2R), interleukin-4
receptor (IL-4R) and interleukin-6 recep-
tor (IL-6R) on peripheral blood lym-
phocytes (PBL) in patients with systemic
lupus erythematosus (SLE); to correlate
the level of expression of these receptors
with SLE disease activity.
Methods-Peripheral blood lymphocytes
were studied by a high sensitivity flow
cytometry technique using monoclonal
antibodies directed against CD25 (IL-2R a
chain), CD122 (IL-2R l chain), CD124
(IL-4R), and CD126 (IL-6R). SLE disease
activity was scored using the SLE Disease
Activity Index, C3 and C4 concentrations,
anti-dsDNA level, and absolute lympho-
cyte count.
Results-Compared with normal con-
trols, PBL from patients with SLE had a
higher percentage ofCD25+ cells (median
20.8% v 16.5%) and a lower percentage of
CD122+ cells (median 13.1% v 22.4%) .
The difference in CD122+ cells was
greater in the CD122WC" population than
the CD122"'g (natural killer cell) popula-
tion. The percentages of CD124+ and
CD126+ PBLs in patients with SLE and
controls were similar. On CD25+ cells, the
relative antigenic level of the IL-2R a
chain was significantly higher in patients
with SLE (median 2.01 v 1.81). The
relative antigenic levels of CD122+,
CD124+ and CD126+ cells were similar in
patients and controls. Neither the per-
centages nor the relative antigenic levels
of all ofthese cytokine receptors were cor-
related with any of the parameters of dis-
ease activity.
Conclusion-Lymphocyte activation in
patients with SLE was evident from the
increase in CD25 expression on PBL, with
a reciprocal decrease in CD122 expres-
sion. As the expression of IL-2R, IL-4R,
IL-6R did not correlate with disease activ-
ity, it seems that these cytokinelreceptor
systems do not play a direct role in disease
activation in SLE.
(J Clin Pathol 1996;49:660-663)
Keywords: cytokine receptors, systemic lupus ery-
thematosus, peripheral blood lymphocytes.
Systemic lupus erythematosus (SLE) is char-
acterised by several functional abnormalities of
the immune system, including impaired T cell
responses and B cell hyper-reactivity. Abnor-
malities of the interleukin-2/interleukin-2 re-
ceptor (IL-2/IL-2R) system have been de-
scribed previously in these patients-for
example, increased serum concentrations of
soluble IL-2R,'-' increased cellular expression
of the Tac (CD25) antigen,6`8 and impaired
production of IL-2 in vitro.27 Interleukin-4
(IL-4) and interleukin-6 (IL-6) were initially
identified as B cell growth and differentiation
factors. It is now known that the main
physiological function of IL-4 is as a regulator
of allergic diseases; IL-6 causes hepatocytes to
synthesise several acute phase proteins. The
role of IL-4 and IL-6 and their corresponding
receptors in autoimmune diseases is not known
but there is evidence suggesting these TH2
cytokines are involved in promoting and
perpetuating B cell hyperactivity and autoanti-
body formation.9 In the present study, we
sought to examine the expression of IL-2R,
IL-4R, IL-6R on peripheral blood lymphocytes
(PBL) of patients with SLE in comparison
with normal individuals, using a sensitive
immunofluorescence technique that detects
low antigenic expression generally missed on
conventional staining. The expression of these
receptors on PBL was correlated with SLE dis-
ease activity. To measure disease activity, we
have chosen the SLE Disease Activity Index
(SLEDAI)' which consists of 24 weighted
clinical and laboratory parameters. Other
markers of SLE disease activity, including C3,
anti-dsDNA, and the absolute lymphocyte
count were also measured for comparison.
Methods
Sixty nine (eight men) consecutive patients
from the Department of Medicine, University
of Hong Kong, who met four or more of the
criteria of the American College of Rheumatol-
ogy for the classification of SLE, were stud-
ied." At the time of study, all patients were
receiving no more than 15 mg prednisolone;
some were also taking 50-100 mg azathio-
prine. There was no difference in drug
treatment between the patients with active and
inactive disease because the former were stud-
ied prior to the augmentation of their steroid
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Table 1 Median (first and third quartiles) ofpercentage ofperipheral blood lymphocytes that express CD25, CD122,
CD124, and CD126
CD25 CD122 CD124 CD126
Normal 16.5 (14.8-20.0) 22.4 (14.05-26.83) 7.9 (6.08-9.7) 26.55 (22.43-33.9)
SLE (overall) 20.8 (16.9-25.3) 13.1 (8.8-18.9) 7.5 (4.2-9) 25.2 (18-29.1)
SLE (SLEDAI < 5) 20.3 (15.2-23.5) 11.25 (8.35-17.3)
SLE (SLEDAI > 9) 16.9 (15.2-23.5) 13.1 (12.85-19.4)
Table 2 Median (first and third quartiles) of the relative antigenic level of CD25, CD122, CD124, and CD126
expressed on peripheral blood lymphocytes
CD25 CD122 CD124 CD126
Normal 1.81 (1.62-2.01) 1.46 (1.18-1.62) 1.34 (1.07-1.49) 1.39 (1.14-1.57)
SLE (overall) 2.01 (1.7-2.18) 1.35 (1.2-1.66) 1.28 (1.16-1.39) 1.39 (1.27-1.52)
SLE (SLEDAI < 5) 2.04 (1.79-2.18) 1.23 (1.16-1.41)
SLE (SLEDAI > 9) 1.87 (1.37-2.19) 1.55 (1.43-1.72)
dosage. For comparison, 51 healthy volunteers
of similar age and sex distribution were
included.
DISEASE ACTIVITY
The SLEDAI'0 was used to assess the disease
activity of each patient during the study. Clin-
ical parameters were scored by two of the
authors who followed the progress of all
patients. Anti-dsDNA antibodies were assayed
by ELISA using the International Reference
Standard for anti-dsDNA antibody. C3 and C4
concentrations were measured using neph-
elometry.
Lymphocytes expressing the cytokine recep-
tors were studied using a high sensitivity flow
cytometry technique, as described previously.'2
Briefly, peripheral blood mononuclear cells
were obtained by Ficoll-Hypaque sedimenta-
tion. The cells were incubated with a mouse
IgG monoclonal antibody, the binding of
which was detected after washing with a bioti-
nylated horse anti-mouse IgG (Vector Labora-
tories, Burlingame, California, USA) followed
by Streptavidin-phycoerythrin (Dako, Glos-
trup, Denmark). The monoclonal antibodies
used included CD25 (from H Zola), CD122
(Immunotech, Marseille, France), CD 124
(Immunotech), and CD126 (Serotec, Oxford,
UK) which bind the IL-2R x chain, the IL-2R
, chain, IL-4R, and IL-6R, respectively. The
same batch of reagents was used throughout
the study. For isotypic control, a mouse mono-
clonal antibody of the same isotype but not
reacting with human lymphocytes, was used.
After staining, the cells were analysed in a
Coulter Profile II flow cytometer. Only cells
with forward and side scatter characteristics of
lymphocytes were gated. The cut-off level was
set to include 2% of the isotypic control cells.
The percentage of positive cells above this cut-
off level and the mean fluorescence channel
number were recorded.
QUALITY CONTROL
Optical alignment of the flow cytometer was
set daily using DNA check standard beads
(Coulter, Hialeah, Florida, USA). The ma-
chine settings were counter checked using Cal-
iBRITE standard beads (Becton Dickinson,
San Jose, California, USA). These beads gave a
mean (SD) fluorescence level of 9.39 (0.10)
between assays. Frozen mononuclear cells were
stained in parallel with test samples during
each assay.
STATISTICS
Two sample comparisons were performed by
the Wilcoxon technique. Correlations between
samples were studied by the Spearman rank
correlation test. Both are non-parametric tests.
Results
EXPRESSION OF CD25 AND CD122 ON PERIPHERAL
BLOOD LYMPHOCYTES
Tables 1 and 2 show the medians, first and
third quartiles of CD25, CD122, CD124, and
CD126 expression on PBL in patients with
SLE and normal controls. Representative
staining patterns of these cytokine receptors
are shown in fig 1. The percentage of PBL that
were CD25+ was significantly higher in patients
with SLE than in controls (p < 0.001). The
relative density of CD25 molecules on CD25+
PBL, as indicated by the mean channel number
of fluorescent cells, was also significantly higher
in patients with SLE (p < 0.05). Expression of
CD25 was similar in controls and patients with
active disease (SLEDAI > 9). However, ex-
pression of CD25 in those with inactive disease
(SLEDAI < 5) was significantly higher than in
normal controls (p < 0.01).
Conversely, a significantly greater pro-
portion of PBL in normal controls were
CD 122+ than in patients with SLE (p < 0.05).
Those patients with inactive disease (SLEDAI
< 5) had a significantly lower percentage of
CD122+ PBL than normal controls (p <
0.05). The difference between patients with
active disease (SLEDAI > 9) and normal con-
trols was not statistically significant (table 1).
There was no difference in the antigenic level
of CD 122+ PBL between patients with SLE
and controls. The difference in the number of
CD122+ cells was greater in the CD122weak
population (SLE 12.4% v controls 19.4%)
than the CD122strong (SLE 1.8% v controls
2.4%) population, although these differences
were not statistically significant. The
CD 1 22stxong cells were known to be natural killer
cells.
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Figurel Expression ofIL-2R, IL-4R and IL-6R on peripheral blood lymphocytes from patients with SLE (fluorescence
level on x axis in log scale; number of cells on y axis in linear scale). (A) Isotypic control; (B) IL-2R a chain (CD25);
(C) IL-2R a chain (CD122); (D) IL-4R (CD124); (E) IL-6R (CD126).
EXPRESSION OF CD124 AND CD126 ON
PERIPHERAL BLOOD LYMPHOCYTES
No significant difference was found -with
regard to the expression of CD124 (IL-4R)
and CD126 (IL-6R) on PBL in patients with
SLE and normal controls.
CORRELATION OF CYTOKINE RECEPTOR
EXPRESSION WITH DISEASE ACTIVITY
Neither the percentage nor the relative anti-
genic level of CD25, CD122, CD124, or
CD126 correlated with disease activity as
scored by SLEDAI, C3 and C4 concentra-
tions, anti-dsDNA level and absolute lym-
phocyte count.
Discussion
Interleukin-2 is an important cytokine pro-
duced by T cells upon activation. It exerts
numerous immunological effects by stimulat-
ing proliferation and lymphokine production
by T cells, B cells and natural killer cells.
Following activation, T cells also express the
IL-2R and become responsive to IL-2. We
show here that the percentage and the relative
density of CD25 expressed on PBL is signifi-
cantly higher in patients with SLE than in nor-
mal controls. This is consistent with several
previous studies"8 which reported an increase
in CD25 expression on PBL of patients with
SLE. In two of these reports,6 7 CD25 expres-
sion was significantly higher in patients with
active disease than in those with inactive
disease or in normal controls. The third study8
reported an increase in the expression ofCD25
in patients with and without active disease,
which suggests that there is no correlation
between CD25 expression and disease activity.
Our study sought to obtain paired data of
CD25 expression and markers of disease activ-
ity and found no correlation between the two.
Furthermore, expression of CD25 on PBL in
patients with SLE with active disease
(SLEDAI > 9) was similar to that in normal
subjects. These findings suggest increased
CD25 expression on PBL may be a constitu-
tive abnormality found only in patients with
inactive SLE. Therefore, expression of CD25
cannot be used as a marker of disease progres-
sion in SLE.
Increased plasma concentrations of IL-2
have been reported in patients with SLE.' 13
This, together with increased expression of
CD25 on PBL, suggests that lymphocytes are
in an activated state in vivo. However, stimula-
tion of lymphocytes from patients with SLE
with mitogens resulted in little increase in
expression of CD256 7 or in production of
IL-22 when compared with stimulation of nor-
mal lymphocytes. This in vitro T cell defect
could reflect exhaustion of activated T cells.
Ishida et all4 demonstrated that the expression
of high affinity IL-2R on these in vitro
activated lymphocytes was lower in cells
obtained from patients with SLE. Further-
more, we found that there was no significant
difference in expression of CD25 on PBL in
patients with active disease and normal sub-
jects. These results suggest that T cells are
exhausted during active disease. Recent studies
have shown that in patients with SLE expres-
sion of Fas is upregulated on blood lym-
phocytes'5 and cultured lymphocytes undergo
apoptosis to a greater degree.'6 Moreover, acti-
vation associated lymphocyte death has been
demonstrated in HIV positive subjects.'7 These
observations suggest that cells activated in vivo,
with upregulation ofCD25 and Fas expression,
in patients with active SLE may subsequently
die via apoptosis.
IL-2R is a complex involving three distinct
protein chains.'8 The a chain (CD25) seems to
c
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be involved in the initial binding of IL-2, and is
highly sensitive to upregulation by activation,
while the 3 and y chains are essential for signal
transduction. The y chain is constitutively
expressed in normal lymphocytes.'9 In normal
cell populations, the ax and f chains are
expressed essentially in a reciprocal manner,
although a small number of cells express
detectable levels of both chains.20 This recipro-
cal relation between the a and ,B chains was
also demonstrated in the present study in lym-
phocytes from patients with SLE. Using
radiolabelled IL-2 instead of monoclonal anti-
body, the expression of p75 on T cells of
patients with SLE was found to be lower than
in normal T cells.2' On phytohaemagglutinin
stimulated blasts, expression of high affinity
IL-2R was also lower in patients with SLE than
normal controls, although there was no differ-
ence in the expression of CD25.14 This
decrease in p75 expression suggests that the
increased CD25 expression may not indicate a
greater responsiveness to IL-2, but rather is a
symptom of persisting activation.
The role of IL-4 and IL-6 in the pathogen-
esis of SLE is not known. It has been reported
that patients with SLE have higher circulating
concentrations of IL-4' and IL-622 than normal
controls. Furthermore, CD4+CD29+ T cells,
which were the major T cells producing IL-6,
were also increased in the circulation of
patients with SLE.'5 It is postulated that
overexpression of these cytokines may contrib-
ute to the B cell hyperactivity and enhanced
antibody synthesis characteristic of this au-
toimmune disease. In the present study, the
level of expression of IL-4R and IL-6R on PBL
of patients with SLE was no different from that
in normal subjects. It would be interesting to
know whether there is any difference in expres-
sion of these receptors on T, B and other lym-
phocyte subsets. Nagafuchi et af4 reported
overexpression of IL-6R on B lymphocytes of
patients with SLE. Further study on these
cytokines and cytokine receptors should help
to delineate the immunological abnormalities
in SLE.
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